293 Predictive genetic biomarkers for the development of peritoneal metastases in colorectal cancer Acad. Sci. USA 2010, 107, 15145–15150. https:// doi.org/10.1073/pnas.1009941107. [51] Bhat, Z.I.; Kumar, B.; Bansal, S.; Naseem, A.; Tiwari, R.R.; Wahabi, K.; Sharma, G.D.; Alam Rizvi, M.M. Association of PARK2 promoter polymorphisms and methylation with colorectal cancer in North Indian population. Gene 2019, 682, 25–32. https://doi.org/10.1016/j. gene.2018.10.010. [52] Gonzalez-Pons, M.; Cruz-Correa, M. Colorectal Cancer Biomarkers: Where Are We Now? Biomed. Res. Int. 2015, 2015, 149014. https:// doi.org/10.1155/2015/149014. [53] Baran, B.; Mert Ozupek, N.; Yerli Tetik, N.; Acar, E.; Bekcioglu, O.; Baskin, Y. Difference between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterol. Res. 2018, 11, 264–273. https://doi. org/10.14740/gr1062w. [54] Akce, M.; Zakka, K.; Jiang, R.; Williamson, S.; Alese, O.; Shaib, W.; Wu, C.; Behera, M.; El-Rayes, B. Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer with Known Microsatellite Instability Status. Front. Oncol. 2021, 11, 592351. https://doi. org/10.3389/fonc.2021.592351. [55] Caputo, F.; Santini, C.; Bardasi, C.; Cerma, K.; Casadei-Gardini, A.; Spallanzani, A.; Andrikou, K.; Cascinu, S.; Gelsomino, F. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. Int. J. Mol. Sci. 2019, 20, 5369. https://doi. org/10.3390/ijms20215369. [56] Cantwell-Dorris, E.R.; O’Leary, J.J.; Sheils, O.M. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 2011, 10, 385–394. https://doi.org/10.1158/1535-7163. Mct-10-0799. [57] Tran, B.; Kopetz, S.; Tie, J.; Gibbs, P.; Jiang, Z.Q.; Lieu, C.H.; Agarwal, A.; Maru, D.M.; Sieber, O.; Desai, J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011, 117, 4623–4632. https:// doi.org/10.1002/cncr.26086. [58] Lee, J.H.; Ahn, B.K.; Baik, S.S.; Lee, K.H. Comprehensive Analysis of Somatic Mutations in Colorectal Cancer with Peritoneal Metastasis. In Vivo 2019, 33, 447–452. https://doi. org/10.21873/invivo.11493. [59] Astrosini, C.; Roeefzaad, C.; Dai, Y.Y.; Dieckgraefe, B.K.; Jöns, T.; Kemmner, W. REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. Int. J. Cancer 2008, 123, 409–413. https://doi. org/10.1002/ijc.23466. [60] Takahashi, Y.; Iwaya, T.; Sawada, G.; Kurashige, J.; Matsumura, T.; Uchi, R.; Ueo, H.; Takano, Y.; Eguchi, H.; Sudo, T.; et al. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer. Ann. Surg. Oncol. 2014, 21, 205–212. https://doi. org/10.1245/s10434-013-3264-3. [61] Shirahata, A.; Shinmura, K.; Kitamura, Y.; Sakuraba, K.; Yokomizo, K.; Goto, T.; Mizukami, H.; Saito, M.; Ishibashi, K.; Kigawa, G.; et al. MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res. 2010, 30, 2689–2692. [62] Nagahara, M.; Nishida, N.; Iwatsuki, M.; Ishimaru, S.; Mimori, K.; Tanaka, F.; Nakagawa, T.; Sato, T.; Sugihara, K.; Hoon, D.S.; et al. Kinesin 18A expression: Clinical relevance to colorectal cancer progression. Int. J. Cancer 2011, 129, 2543–2552. https://doi.org/10.1002/ijc.25916. [63] Yang, Y.Z.; Hu, W.M.; Xia, L.P.; He, W.Z. Association between somatic RET mutations and clinical and genetic characteristics in patients with metastatic colorectal cancer. Cancer Med. 2021, 10, 8876–8882. https://doi.org/10.1002/ cam4.4400. [64] Sakuraba, K.; Yasuda, T.; Sakata, M.; Kitamura, Y.H.; Shirahata, A.; Goto, T.; Mizukami, H.; Saito, M.; Ishibashi, K.; Kigawa, G.; et al. Down-regulation of Tip60 gene as a potential marker for the malignancy of colorectal cancer. Anticancer Res. 2009, 29, 3953–3955. [65] Stein, M.K.; Williard, F.W.; Xiu, J.; Tsao, M.W.; Martin, M.G.; Deschner, B.W.; Dickson, P.V.; Glazer, E.S.; Yakoub, D.; Shibata, D.; et al. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. J. Surg. Oncol. 2020, 121, 1320–1328. https://doi.org/10.1002/jso.25899. [66] Brannon, A.R.; Vakiani, E.; Sylvester, B.E.; Scott, S.N.; McDermott, G.; Shah, R.H.; Kania, K.; Viale, A.; Oschwald, D.M.; Vacic, V.; et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 2014, 15, 454. https://doi.org/10.1186/ s13059-014-0454-7. [67] Lenos, K.J.; Bach, S.; Ferreira Moreno, L.; Ten Hoorn, S.; Sluiter, N.R.; Bootsma, S.; Vieira Braga, F.A.; Nijman, L.E.; van den Bosch, T.; Miedema, D.M.; et al. Molecular characterization of colorectal cancer related peritoneal metastatic disease. Nat. Commun. 2022, 13, 4443. https:// doi.org/10.1038/s41467-022-32198-z. [68] Priestley, P.; Baber, J.; Lolkema, M.P.; Steeghs, N.; de Bruijn, E.; Shale, C.; Duyvesteyn, K.; Haidari, 12
RkJQdWJsaXNoZXIy MTk4NDMw